How circulating tumor cells escape from multidrug resistance: Translating molecular mechanisms in metastatic breast cancer treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 625-627

  Gradilone, Angela ^a   Raimondi, Cristina ^b   Naso, Giuseppe ^b   Silvestri, Ida ^a   Repetto, Lazzaro ^a   Palazzo, Antonella ^b   Gianni, Walter ^a   Frati, Luigi ^a,b   Cortesi, Enrico ^b   Gazzaniga, Paola ^a  

^a INRCA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

anthracyclines; circulating tumor cells; multidrug resistance

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CIRCULATING TUMOR CELL; GENE EXPRESSION; HUMAN; METASTASIS; MULTIDRUG RESISTANCE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING;

EID: 81855177034     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181f94596     Document Type: Article

References (5)

1. Türk D, Szakács G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel. 2009;12:246-252.
2. Leonard RC, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009;18:218-224.
3. Dotan E, Cohen SJ, Alpaugh KR, et al. Circulating tumor cells: evolving evidence and future challenges. Oncologist. 2009;14: 1070-1082.
4. Gazzaniga P, Naso G, Gradilone A, et al. Chemosensitivity profile assay of circulating cancer cells (CTCs): prognostic and predictive value in epithelial tumors. Int J Cancer. 2010;126: 2437-2447.
5. Michieli M, Damiani D, Ermacora A, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol. 1999;106:92-99.